S 6925 — Relates to capping cost sharing for antiviral COVID-19 therapeutics
Congress · introduced 2025-03-27
Requires insurance companies, medical expense indemnity corporations, hospital service corporations, health service corporations and medical assistance programs to provide coverage for prescribed antiviral therapeutics approved by the food and drug administration for the treatment of COVID-19 at no cost to the patient.
Latest action: 2025-03-27 — IN_SENATE_COMM
Sponsors
- Brad Hoylman-Sigal (—, NY-47) — sponsor · 2025-03-27
Action timeline
- · senate — REFERRED TO INSURANCE
Text versions
Connected on the graph
Inbound (1)
| date | from | type | amount | role | source |
|---|---|---|---|---|---|
| 2025-03-27 | Brad Hoylman-Sigal | sponsor_of_bill | — | sponsor | sponsorship |
Who matters
Members ranked by combined influence on this bill: role (sponsor 5 / cosponsor 1), capped speech count from the Congressional Record, and recorded-vote engagement.
| # | Member | Role | Speeches | Voted | Score |
|---|---|---|---|---|---|
| 1 | Brad Hoylman-Sigal (—, state_upper NY-47) | sponsor | 0 | — | 5 |
Predicted vote
Aggregated from: actual roll-call votes (when present) → sponsor → cosponsor → party median (predicts YES when ≥25% of the caucus sponsored/cosponsored). Each row labels its confidence tier so you can see why a position was predicted.
0 predicted yes (0%) · 543 predicted no (100%) · 0 unknown (0%)
By party: · R: 0 yes / 277 no · D: 0 yes / 263 no · I: 0 yes / 3 no
Activity
Every typed-graph event involving this entity, newest first. Each row is one edge in the influence graph; click the date to jump to its provenance.
- 2025-03-27 · sponsored by Brad Hoylman-Sigal (sponsor) · sponsorship